Methylene Blue Inhibits the SARS-CoV-2 Spike–ACE2 Protein-Protein Interaction–a Mechanism that can Contribute to its Antiviral Activity Against COVID-19
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Methylene Blue Inhibits the SARS-CoV-2 Spike–ACE2 Protein-Protein Interaction–a Mechanism that can Contribute to its Antiviral Activity Against COVID-19
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-01-14
DOI
10.3389/fphar.2020.600372
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chloroquine for the 2019 novel coronavirus SARS-CoV-2
- (2020) Philippe Colson et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
- (2020) Wanbo Tai et al. Cellular & Molecular Immunology
- The Science Underlying COVID-19: Implications for the Cardiovascular System
- (2020) Peter P. Liu et al. CIRCULATION
- Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
- (2020) Zhenzhen Fan et al. EMBO Molecular Medicine
- The many faces of the anti-COVID immune response
- (2020) Santosha A. Vardhana et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
- (2020) David E. Gordon et al. NATURE
- Cell entry mechanisms of SARS-CoV-2
- (2020) Jian Shang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cytokine release syndrome in severe COVID-19
- (2020) John B. Moore et al. SCIENCE
- Rapid repurposing of drugs for COVID-19
- (2020) R. Kiplin Guy et al. SCIENCE
- Estimating the burden of SARS-CoV-2 in France
- (2020) Henrik Salje et al. SCIENCE
- Why COVID-19 Silent Hypoxemia Is Baffling to Physicians
- (2020) Martin J. Tobin et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics
- (2020) Hariharan Sivaraman et al. Annual Review of Pharmacology and Toxicology
- Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle
- (2020) Clarisse Salgado-Benvindo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Discovering small-molecule therapeutics against SARS-CoV-2
- (2020) Vaibhav Tiwari et al. DRUG DISCOVERY TODAY
- Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
- (2020) Serena Di Cosimo et al. EUROPEAN JOURNAL OF CANCER
- The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
- (2020) Qing Ye et al. JOURNAL OF INFECTION
- Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities
- (2020) Siyu Xiu et al. JOURNAL OF MEDICINAL CHEMISTRY
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
- (2020) Chee Wah Tan et al. NATURE BIOTECHNOLOGY
- Candidate drugs against SARS-CoV-2 and COVID-19
- (2020) Dwight L. McKee et al. PHARMACOLOGICAL RESEARCH
- How does SARS-CoV-2 cause COVID-19?
- (2020) Nicholas J. Matheson et al. SCIENCE
- A single unified model for fitting simple to complex receptor response data
- (2020) Peter Buchwald Scientific Reports
- Application of methylene blue -vitamin C –N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial
- (2020) Daryoush Hamidi Alamdari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Methylene blue inhibits the replication of SARS-Cov-2 in vitro
- (2020) Mathieu Gendrot et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology
- (2019) Martin C. Michel et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
- (2018) Michael J Curtis et al. BRITISH JOURNAL OF PHARMACOLOGY
- Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial
- (2018) Alassane Dicko et al. LANCET INFECTIOUS DISEASES
- Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40–CD154 Costimulatory Protein-Protein Interaction
- (2018) Damir Bojadzic et al. MOLECULES
- Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010
- (2017) Nicholas S. Downing et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Small-Molecule Inhibitors of the CD40–CD40L Costimulatory Protein–Protein Interaction
- (2017) Jinshui Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
- (2016) Duncan E. Scott et al. NATURE REVIEWS DRUG DISCOVERY
- Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction
- (2014) Yun Song et al. BRITISH JOURNAL OF PHARMACOLOGY
- Modulators of Protein–Protein Interactions
- (2014) Lech-Gustav Milroy et al. CHEMICAL REVIEWS
- Plasma Treated with Methylene Blue and Light: Clinical Efficacy and Safety Profile
- (2013) Miguel Lozano et al. TRANSFUSION MEDICINE REVIEWS
- NIH Image to ImageJ: 25 years of image analysis
- (2012) Caroline A Schneider et al. NATURE METHODS
- The food colorant erythrosine is a promiscuous protein–protein interaction inhibitor
- (2011) Lakshmi Ganesan et al. BIOCHEMICAL PHARMACOLOGY
- “Lest we forget you — methylene blue …”
- (2011) R. Heiner Schirmer et al. NEUROBIOLOGY OF AGING
- Designing Focused Chemical Libraries Enriched in Protein-Protein Interaction Inhibitors using Machine-Learning Methods
- (2010) Christelle Reynès et al. PLoS Computational Biology
- Suramin inhibits the CD40–CD154 costimulatory interaction: A possible mechanism for immunosuppressive effects
- (2009) Emilio Margolles-Clark et al. BIOCHEMICAL PHARMACOLOGY
- Rationalizing the chemical space of protein–protein interaction inhibitors
- (2009) Olivier Sperandio et al. DRUG DISCOVERY TODAY
- Small-molecule costimulatory blockade: organic dye inhibitors of the CD40–CD154 interaction
- (2009) Emilio Margolles-Clark et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- High absolute bioavailability of methylene blue given as an aqueous oral formulation
- (2008) Ingeborg Walter-Sack et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Protein therapeutics: a summary and pharmacological classification
- (2007) Benjamin Leader et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More